GLP-1 AGONISM / GIP RECEPTOR ANTAGONISM

MariTide

A long-acting obesity candidate designed for monthly or less-frequent dosing, now advancing through a broad Phase 3 MARITIME program.

Evidence Maturity · M4 — Advanced clinical Investigational — Phase 3
Evidence reviewed: September 19, 2026Source-labeled

Signal summary

MariTide (maridebart cafraglutide; AMG 133) is differentiated less by a claim of muscle preservation than by its mechanism and unusually infrequent dosing strategy.

Signal interpretation: The strongest current signal is durability and dosing frequency. Amgen is testing monthly, every-eight-week and quarterly maintenance approaches, but body-composition superiority is not yet established.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

Phase 2 maridebart cafraglutide trial

Population
592 participants: 465 in obesity cohort and 127 in obesity with diabetes cohort.
Doses and administration studied
Subcutaneous 140, 280 or 420 mg every four weeks; additional obesity arms tested 420 mg every eight weeks and escalation variants.
Duration
52 weeks
Reported finding / status
Treatment-policy weight loss in the obesity cohort ranged from 12.3% to 16.2%, versus 2.5% with placebo.
Interpretation and limitations
Results vary by cohort, dose and estimand. Gastrointestinal events were common. These phase 2 regimens do not define future approved dosing.

Source tier B · Read the original study or record

Outcome Evidence Strength

Weight change3/5
Fat-mass change0/5
Lean-mass change0/5
Strength / function benefit0/5

Weight: published phase 2 RCT. Composition and functional advantages are not established by this weight-efficacy report.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

What is actually established?

  • Amgen reports multiple ongoing Phase 3 MARITIME studies in obesity, cardiovascular outcomes, heart failure and obstructive sleep apnea.
  • MARITIME-SWITCH is studying people moving from weekly semaglutide or tirzepatide to less-frequent MariTide schedules.
  • Long-term Phase 2 follow-up supported maintenance of prior weight loss with lower-frequency dosing in many participants.

What is not established?

  • MariTide is not FDA-approved.
  • Less-frequent dosing does not itself prove better adherence, durability or outcomes in real-world use.
  • A body-composition advantage over established incretins has not been demonstrated.

Evidence sources

A = regulatory/official • B = peer-reviewed randomized/meta-analysis • C = peer-reviewed review/observational • D = registered trial • E = sponsor-reported • F = preclinical

Source tier E — Sponsor pipeline update
Amgen Q2 2026 MARITIME program update
Source tier D — Registered Phase 3 extension
MARITIME-1 extension trial

Last evidence review: September 19, 2026.

Educational use only. This page summarizes research evidence and regulatory status. Study doses describe research, not prescribing instructions. This page does not provide personalized dosing, self-use protocols, sourcing, or a recommendation to use this therapy.